跳至主要内容
临床试验/IRCT2017100136491N1
IRCT2017100136491N1招募中2 期

Evaluation of clinical and histopathological efficacy of carboplatin and gemcitabine as second line neoadjuvant therapy in locally advanced breast cancer patients

Ministry of Research, Shiraz University of Medical Sciences, Pharmaceutical Sciences Research Center0 个研究点目标入组 50 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 60 years(—)
性别
Female

入选标准

  • Female patients; Diagnosed with locally advanced breast cancer; 18 to 60 years of age. Exclusion criteria: Evidence of metastasis; Inflammatory breast cancer; Abnormal kidney function (Serum creatinine > 1.5 mg/dl); Abnormal liver function (Bilirubin and Serum transaminase > 2xULN); Abnormal Bone marrow function (Abnormal hemoglobin, WBC and platelet count)

排除标准

  • 未提供

研究者

发起方
Ministry of Research, Shiraz University of Medical Sciences, Pharmaceutical Sciences Research Center

相似试验